Updated:
HITE Hedge Asset Management LLC
HITE HEDGE ASSET MANAGEMENT LLC is an SEC-registered investment adviser in BRAINTREE, MA, registered since 2012. The firm manages approximately $2.2 billion in...
HITE Hedge Asset Management LLC
HITE HEDGE ASSET MANAGEMENT LLC is an SEC-registered investment adviser in BRAINTREE, MA, registered since 2012. The firm manages approximately $2.2 billion in assets. It has 21 employees and 13 investment advisers.
General information
Firm type
Asset Manager
Year founded
2010
Location
Region
North America
Country
United States
City
Braintree
Corporate office
New York, NY, United States
Principals
John J. Hite
Chief Executive Officer & Chief Investment Officer
Sector focus
Frequently asked questions
Who runs investment decisions at HITE Hedge Asset Management?
John J. Hite serves as CEO and CIO, overseeing all investment decisions. He founded the firm in 2010. Public filings show Hite as the lead portfolio manager for the firm's disclosed positions.
What types of healthcare investments does HITE pursue?
The firm invests across public equities, private placements, PIPEs, and structured financing. Recorded holdings span biopharmaceuticals, medical devices, and diagnostics. Examples include positions in AveXis (acquired by Novartis in 2018) and Mirati Therapeutics (acquired by Bristol Myers Squibb in 2023).
Does HITE participate in fund commitments or only direct deals?
HITE primarily makes direct stock and structured investments rather than committing to external funds. The firm's model involves placing capital directly into healthcare companies, both public and private, rather than acting as a fund of funds.
Which sectors does HITE explicitly avoid?
HITE explicitly avoids all sectors outside healthcare. The firm's website and public communications describe it as a healthcare-dedicated manager, passing on technology, energy, consumer, and other non-biomedical opportunities.
What is the longevity of HITE's mandate?
HITE has maintained its healthcare-only mandate since its founding in 2010 — over 14 years. This consistent focus through multiple market cycles, including the COVID-19 pandemic and the 2020–2023 biotech bear market, provides a track record of discipline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: